ContextVision AB (OSL:CONTX) ROCE %: 4.97% (As of Mar. 2026)


OSL:CONTX ContextVision AB OSL:CONTX
81 GF Score
Price kr3.53
GF Value kr5.13
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ContextVision AB ROCE %?

ContextVision AB OSL:CONTX +6.97% 81 ROCE % is 4.97% as of Mar. 2026. GuruFocus rates OSL:CONTX with a GF Score™ of 81/100 and a GF Value™ of kr5.13 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ContextVision AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 4.97%.

ContextVision AB  (OSL:CONTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ContextVision AB ROCE % Related Terms

ContextVision AB ROCE % Historical Data

* Premium members only.

The historical data trend for ContextVision AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ContextVision AB ROCE % Chart

ContextVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.62 73.01 57.91 34.05 0.27

ContextVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.10 2.06 -1.44 17.30 4.97
OSL:CONTX
81GF Score
ContextVision AB OSL:CONTX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ContextVision AB ROCE % Calculation

ContextVision AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.291/( ( (133.055 - 28.937) + (135.785 - 25.597) )/ 2 )
=0.291/( (104.118+110.188)/ 2 )
=0.291/107.153
=0.27 %

ContextVision AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=5.304/( ( (135.785 - 25.597) + (130.97 - 27.822) )/ 2 )
=5.304/( ( 110.188 + 103.148 )/ 2 )
=5.304/106.668
=4.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.97% mean?
ContextVision AB (OSL:CONTX) has a ROCE % of 4.97% as of Mar. 2026.
Is ContextVision AB's ROCE % too high?
ContextVision AB's current ROCE % is 4.97%. The Healthcare Providers & Services industry median ROCE % is 6.43. ContextVision AB's value of 4.97% is 22.7% below this industry median. Overall, ContextVision AB has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ContextVision AB's ROCE % compare to VEEV and BTSG?
ContextVision AB's ROCE % of 4.97% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.43. ContextVision AB's value of 4.97% is 22.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.43, based on 645 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ContextVision AB's current ROCE % of 4.97% is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ContextVision AB's current ROCE % is 4.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContextVision AB stock overvalued right now?
Based on GuruFocus' analysis, ContextVision AB (OSL:CONTX) is currently considered Significantly Undervalued. The stock's GF Value™ is kr5.13, compared to a current price of kr3.53 — trading 31.2% below its estimated fair value. The current ROCE % is 4.97% and 22.7% below the Healthcare Providers & Services industry median of 6.43. ContextVision AB's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ContextVision AB (OSL:CONTX), the current ROCE % is 4.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ContextVision AB (OSL:CONTX) Overvalued in 2026?

Based on GuruFocus' analysis, ContextVision AB stock appears to be undervalued. The current stock price of kr3.53 is trading 31.2% below its estimated GF Value™ of kr5.13. GuruFocus considers ContextVision AB to be Significantly Undervalued.

Key valuation signals for OSL:CONTX:

  • ROCE %: 4.97%
  • GF Value™: kr5.13 vs. price of kr3.53 (31.2% below fair value)
  • GF Score™: 81/100 with 2 warning signs
  • Industry Position: 22.7% below the Healthcare Providers & Services median

No single metric tells the full story. See the OSL:CONTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ContextVision AB Business Description

Other Exchanges COVo:Sweden
Address Gamla Brogatan 26, Stockholm, SWE, SE-111 20
ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. Its geographical segments are Asia, Europe, and America.
81GF Score

Get the complete analysis for OSL:CONTX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.53
Price
kr5.13
GF Value